**Table S3. Clinical and genetic characteristics of somatic copy number alteration clusters.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Cluster A****(n=58)** | **Cluster B****(n=66)** | **Cluster C****(n=30)** |
| **Histology, N (%)** |  |  |  |
|  Clear cell | 4 (6.9%) | 2 (3.0%) | 4 (13.3%) |
|  Endometrioid, Grade 1 | 1 (1.7%) | 13 (19.7%) | 2 (6.7%) |
|  Endometrioid, Grade 2 | 2 (3.4%) | 16 (24.2%) | 3 (10%) |
|  Endometrioid, Grade 3 | 5 (8.6%) | 14 (21.2%) | 6 (20%) |
|  Mixed | 3 (5.2%) | 6 (9.1%) | 2 (6.7%) |
|  Carcinosarcoma | 16 (27.6%) | 9 (13.6%) | 5 (16.7%) |
|  Serous | 24 (41.4%) | 5 (7.6%) | 8 (26.7%) |
|  Other | 3 (5.2%) | 1 (1.5%;) | 0 |
| **Tumor collection time, N (%)** |  |  |  |
|  Pre-chemotherapy | 33 (56.9%) | 38 (57.6%) | 20 (66.7%) |
|  Post-chemotherapy | 25 (43.1%) | 28 (42.4%) | 10 (33.3%) |
| **Best response to 1st-line chemotherapy, N (%)** |  |  |  |
|  Total Number Treated | 52 (89.7%) | 42 (63.6%) | 27 (90.0%) |
|  Complete Response | 37 (71.2%) | 22 (52.4%) | 14 (51.9%) |
|  Partial Response | 7 (13.5%) | 10 (23.8%) | 6 (22.2%) |
|  Stable Disease | 0 | 1 (2.4%) | 0 |
|  Progression of Disease | 6 (11.5%) | 4 (9.5%) | 5 (18.5%) |
|  Not Evaluable | 2 (3.8%) | 5 (11.9%) | 2 (7.4%) |
| **Genes altered, N (%)** |  |  |  |
| *PIK3CA* | 26 (44.8%) | 24 (36.4%) | 14 (46.7%) |
| *PTEN* | 8 (13.8%) | 27 (40.9%) | 8 (26.7%) |
| *PIK3R1* | 12 (20.7%) | 20 (30.3%) | 6 (20%) |
| *AKT1* | 2 (3.4%) | 7 (10.6%) | 1 (3.3%) |
| *FGFR1* | 6 (10.3%) | 2 (3.0%) | 2 (6.7%) |
| *FGFR2* | 3 (5.2%) | 6 (9.1%) | 4 (13.3%) |
| *ERBB2* | 6 (10.3%) | 9 (13.6%) | 4 (13.3%) |
| *ERBB3* | 3 (5.2%) | 4 (6.1%) | 4 (13.3%) |
| *KRAS* | 12 (20.7%) | 20 (30.3%) | 3 (10.0%) |
| *FBXW7* | 7 (12.1%) | 9 (13.6%) | 3 (10.0%) |
| *CTNNB1* | 1 (1.7%) | 22 (33.3%) | 0 (0.0%) |
| *PPP2R1A* | 10 (17.2%) | 6 (9.1%) | 5 (16.7%) |
| *ARID1A* | 6 (10.3%) | 29 (43.9%) | 8 (26.7%) |
| *KMT2D* | 5 (8.6%) | 13 (19.7%) | 5 (16.7%) |
| *CCNE1* | 8 (13.8%) | 3 (4.5%) | 3 (10.0%) |
| *MYC* | 5 (8.6%) | 5 (7.6%) | 2 (6.7%) |
| *TP53* | 50 (86.2%) | 18 (27.3%) | 20 (66.7%) |